Dr. Reddy’s Laboratories announces the launch of an authorized generic version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market

April 15, 2020 Praveen Business Comments Off on Dr. Reddy’s Laboratories announces the launch of an authorized generic version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System.

The combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.

NitroDur® is a trademark of USpharma Ltd.

Related Articles

Business

Personalised medicine is a new thing fast gaining momentum: Deepak Sapra, CEO of Dr Reddy’s Laboratories

May 24, 2024 Mansi Praharaj Business Comments Off on Personalised medicine is a new thing fast gaining momentum: Deepak Sapra, CEO of Dr Reddy’s Laboratories

Hyderabad, May 24, 2024….The Technology enables drug discovery faster, more efficiently and cheaper, said Mr Deepak Sapra, CEO of Dr. Reddy’s Laboratories while delivering an opening address at DXEM 2024–a day-long Summit on Navigating Digital […]

Business

Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

July 15, 2020 team Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. July 14, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch […]